A Phase 2 interventional study of EPI-743 in Leigh Syndrome, sponsored by PTC Therapeutics. Completed at 4 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.
Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2014, is one of 5 in phase 2, and was the 8th registered.
20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.
Browse Leigh Disease studies →6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 0 days–100 yrs
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 4 wk–115 yrs · Healthy volunteers
Columbia University · Sites in United States, Canada
Healthy volunteers
Sanford Health · Sites in United States
Matthew Demczko · Sites in United States
Ages 6 mo–55 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 2
First in 2010; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is close to the median of 31 across 10 interventional studies indexed under Leigh Disease.
Median enrollment 35 across the 7 interventional studies, 750 across the 6 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 8 most frequent:
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
PTC Therapeutics has 5 studies filed under Leigh Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Leigh Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Leigh Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.
To monitor the long-term safety and neurodevelopmental effects of EPI-743 on children who complete the EPI743-12-002 placebo-controlled trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
Drug: EPI-743
EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.
Also known as: Vincerinone, Vatiquinone
Disease Severity as Measured by Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3 Score
NPMDS is a validated scale to assess the mitochondrial disease progression.
Time frame: Baseline up to Month 36
Number of Participants With Dose-Limiting Serious Adverse Events (SAEs)
Time frame: Baseline up to Month 36
Bayley Scales of Infant Development-III Score (Participants Age 0-3)
Effect of EPI-743 on neurodevelopment will be measured by Bayley Scales of Infant Development-III score.
Time frame: Baseline up to Month 24
Wechsler Scale of Intelligence and Movement Assessment Battery Score for Children (Participants Age 4-18)
Effect of EPI-743 on neuromuscular function will be assessed by Wechsler Scale of Intelligence and Movement Assessment Battery score.
Time frame: Baseline up to Month 24
Barry-Albright Dystonia Scale Score
Neuromuscular function will be assessed by Barry-Albright Dystonia Scale score.
Time frame: Baseline up to Month 24
Gross Motor Function Measure
Neuromuscular function will be assessed by gross motor function measure.
Time frame: Baseline up to Month 24
Awake Oxygen Saturation Levels
Effect of EPI-743 on respiratory function will be measured by awake oxygen saturation levels.
Time frame: Baseline up to Month 24
Total Ventilator Days and Total Intensive Care Unit Days
Time frame: Baseline up to Month 24
Number of Participants With Pneumonia Episodes and Tracheostomy
Time frame: Baseline up to Month 24
Total Number of Mortalities, Medical Encounters, Hospitalizations, and Hospital Days
Time frame: Baseline up to Month 24
Health-Related Quality of Life as Measured by NPMDS Section 4 Score
Time frame: Baseline up to Month 24
Glutathione Cycle Biomarkers Level
Time frame: Baseline up to Month 24
Ran from Jan 2014 to primary completion in Oct 2023, 116 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha-tocotrienol quinone